These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34291036)

  • 21. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
    Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
    Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Present and Future of Novel Protein Degradation Technology.
    Xia L; Liu W; Song Y; Zhu H; Duan Y
    Curr Top Med Chem; 2019; 19(20):1784-1788. PubMed ID: 31644408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PROTACting the kinome with covalent warheads.
    Chatterjee DR; Kapoor S; Jain M; Das R; Chowdhury MG; Shard A
    Drug Discov Today; 2023 Jan; 28(1):103417. PubMed ID: 36306996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
    He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triazol: a privileged scaffold for proteolysis targeting chimeras.
    Xia LW; Ba MY; Liu W; Cheng W; Hu CP; Zhao Q; Yao YF; Sun MR; Duan YT
    Future Med Chem; 2019 Nov; 11(22):2919-2973. PubMed ID: 31702389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs.
    Girardini M; Maniaci C; Hughes SJ; Testa A; Ciulli A
    Bioorg Med Chem; 2019 Jun; 27(12):2466-2479. PubMed ID: 30826187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and pharmaceutical applications of proteolysis-targeting chimeric molecules.
    Liang Y; Nandakumar KS; Cheng K
    Biochem Pharmacol; 2020 Dec; 182():114211. PubMed ID: 32866456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PROTACs: great opportunities for academia and industry.
    Sun X; Gao H; Yang Y; He M; Wu Y; Song Y; Tong Y; Rao Y
    Signal Transduct Target Ther; 2019; 4():64. PubMed ID: 31885879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Light-Controllable PROTACs for Temporospatial Control of Protein Degradation.
    Liu J; Peng Y; Wei W
    Front Cell Dev Biol; 2021; 9():678077. PubMed ID: 34350175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-Stage Strategy for Development of Proteolysis Targeting Chimeras and its Application for Estrogen Receptor Degraders.
    Roberts BL; Ma ZX; Gao A; Leisten ED; Yin D; Xu W; Tang W
    ACS Chem Biol; 2020 Jun; 15(6):1487-1496. PubMed ID: 32255606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteolysis targeting chimeras (PROTACs) in cancer therapy.
    Ocaña A; Pandiella A
    J Exp Clin Cancer Res; 2020 Sep; 39(1):189. PubMed ID: 32933565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted protein degradation by PROTACs.
    Neklesa TK; Winkler JD; Crews CM
    Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective.
    Yang X; Yin H; Kim RD; Fleming JB; Xie H
    Target Oncol; 2021 Jan; 16(1):1-12. PubMed ID: 33369705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PROTACs: Walking through hematological malignancies.
    Bou Malhab LJ; Alsafar H; Ibrahim S; Rahmani M
    Front Pharmacol; 2023; 14():1086946. PubMed ID: 36909156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16.
    Zhang X; Crowley VM; Wucherpfennig TG; Dix MM; Cravatt BF
    Nat Chem Biol; 2019 Jul; 15(7):737-746. PubMed ID: 31209349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy.
    Chen X; Shen H; Shao Y; Ma Q; Niu Y; Shang Z
    Transl Androl Urol; 2021 Feb; 10(2):954-962. PubMed ID: 33718095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Controlling PROTACs with Light.
    Verma S; Manna D
    ChemMedChem; 2020 Jul; 15(14):1258-1261. PubMed ID: 32558301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
    Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
    Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.